ASTRAZENECA DL-,25 SP.ADR
ASTRAZENECA DL-,25 SP.ADR/ US0463531089 /
ZEGA
08/10/2024 12:32:06
|
Chg.
-1.00
|
Volume |
Bid12:32:10 |
Ask12:32:10 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
69.00EUR
|
-1.43%
|
0 Turnover: 0.00 |
69.00Bid Size: 300 |
70.50Ask Size: 300 |
216.36 bill.EUR |
- |
- |
Business description
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Management board & Supervisory board
CEO |
Pascal Soriot |
Management board |
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
Supervisory board |
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg, Anna Manz |
Company calendar
CW 46 | 12/11/2024
Interim Report 3rd Quarter/9 Months
|